These projects were made possible from Cure Alzheimer's Fund support.
Project Description | Researchers | Funding |
---|---|---|
Microglial-Specific INPP5D Knockdown Modulates Behavior, Amyloidosis and Tauopathy in Alzheimer’s Mouse Models |
2022 $217,327 |
|
VGF-Derived Peptide Therapy for Alzheimer’s Disease: Studies of Mouse and Human TLQP-21 and its Receptor, C3aR1 |
2020, 2024 $345,000 |
|
VGF, a Novel Therapeutic Effector of Alzheimer’s Disease Pathogenesis and Progression |
2017, 2019 $300,000 |
These published papers resulted from Cure Alzheimer’s Fund support.
Pan, A. L., Audrain, M., Sakakibara, E., Joshi, R., Zhu, X., Wang, Q., Wang, M., Beckmann, N. D., Schadt, E. E., Gandy, S., Zhang, B., Ehrlich, M. E., & Salton, S. R. Dual-specificity protein phosphatase 6 (DUSP6) overexpression reduces amyloid load and improves memory deficits in male 5xFAD mice, Frontiers in Aging Neuroscience, June 28, 2024, Read More
El Gaamouch, F., Audrain, M., Lin, W. J., Beckmann, N., Jiang, C., Hariharan, S., Heeger, P. S., Schadt, E. E., Gandy, S., Ehrlich, M. E., & Salton, S. R. VGF-derived peptide TLQP-21 modulates microglial function through C3aR1 signaling pathways and reduces neuropathology in 5xFAD mice, Molecular Neurodegenration, January 10, 2020, Read More
Beckmann, N. D., Lin, W. J., Wang, M., … Gandy, S., Tu, Z., Ehrlich, M. E., Zhang, B., Schadt, E. E. Multiscale causal networks identify VGF as a key regulator of Alzheimer’s disease, Nature Communications, August 7, 2020, Read More
Pan, A. L., Audrain, M., Sakakibara, E., Joshi, R., Zhu, X., Wang, Q., Wang, M., Beckmann, N. D., Schadt, E. E., Gandy, S., Zhang, B., Ehrlich, M. E., & Salton, S. R. Dual-Specificity Protein Phosphatase 4 (DUSP4) Overexpression Improves Learning Behavior Selectively in Female 5xFAD Mice, and Reduces β-Amyloid Load in Males and Females, Cells, December 1, 2022, Read More
Haure-Mirande, J. V., Audrain, M., Fanutza, T., Kim, S. H., Klein, W. L., Glabe, C., Readhead, B., Dudley, J. T., Blitzer, R. D., Wang, M., Zhang, B., Schadt, E. E., Gandy, S., & Ehrlich, M. E. Deficiency of TYROBP, an adaptor protein for TREM2 and CR3 receptors, is neuroprotective in a mouse model of early Alzheimer’s pathology, Acta Neuropathologica, June 13, 2017, Read More
Gandy, S., & Ehrlich, M. E. miR155, TREM2, INPP5D: Disease stage and cell type are essential considerations when targeting clinical interventions based on mouse models of Alzheimer’s amyloidopathy, Journal of Neuroinflammation, September 25, 2023, Read More
Ruiz, H. H., Chi, T., Shin, A. C., Lindtner, C., Hsieh, W., Ehrlich, M., Gandy, S., & Buettner, C. Increased susceptibility to metabolic dysregulation in a mouse model of Alzheimer’s disease is associated with impaired hypothalamic insulin signaling and elevated BCAA levels, Alzheimer's & Dementia, February 28, 2016, Read More
Audrain, M., Haure-Mirande, J. V., Wang, M., Kim, S. H., Fanutza, T., Chakrabarty, P., Fraser, P., St George-Hyslop, P. H., Golde, T. E., Blitzer, R. D., Schadt, E. E., Zhang, B., Ehrlich, M. E., & Gandy, S. Integrative approach to sporadic Alzheimer’s disease: deficiency of TYROBP in a tauopathy mouse model reduces C1q and normalizes clinical phenotype while increasing spread and state of phosphorylation of tau, Molecular Psychiatry, October 3, 2018, Read More
Kim, S. H., Fraser, P. E., Westaway, D., St George-Hyslop, P. H., Ehrlich, M. E., & Gandy, S. Group II metabotropic glutamate receptor stimulation triggers production and release of Alzheimer’s amyloid beta (42) from isolated intact nerve terminals, Journal of Neuroscience, March 17, 2010, Read More
Knight, E. M., Kim, S. H., Kottwitz, J. C., Hatami, A., Albay, R., Suzuki, A., Lublin, A., Alberini, C. M., Klein, W. L., Szabo, P., Relkin, N. R., Ehrlich, M., Glabe, C. G., Gandy, S., & Steele, J. W. Effective anti-Alzheimer A beta therapy involves depletion of specific A beta oligomer subtypes, Neurology Neuroimmunology & Neuroinflammation, May 10, 2016, Read More
Steele, J. W., Kim, S. H., Cirrito, J. R., Verges, D. K., Restivo, J. L., Westaway, D., Fraser, P., Hyslop, P. S., Sano, M., Bezprozvanny, I., Ehrlich, M. E., Holtzman, D. M., & Gandy, S. Acute dosing of latrepirdine (Dimebon), a possible Alzheimer therapeutic, elevates extracellular amyloid-beta levels in vitro and in vivo, Molecular Neurodegeneration, December 17, 2009, Read More
Bose, M., Farias Quipildor, G., Ehrlich, M. E., & Salton, S. R. Intranasal Peptide Therapeutics: A Promising Avenue for Overcoming the Challenges of Traditional CNS Drug Development, Cells, November 16, 2022, Read More
T., Kim, S. H., Heja, S., Readhead, B., Dudley, J. T., Blitzer, R. D., Schadt, E. E., Zhang, B., Gandy, S., & Ehrlich, M. E. Integrative approach to sporadic Alzheimer’s disease: deficiency of TYROBP in cerebral Aβ amyloidosis mouse normalizes clinical phenotype and complement subnetwork molecular pathology without reducing Aβ burden, Molecular Psychiatry, October 3, 2018, Read More
Haure-Mirande, J. V., Audrain, M., Ehrlich, M. E., & Gandy, S. Microglial TYROBP/DAP12 in Alzheimer’s disease: Transduction of physiological and pathological signals across TREM2, Molecular Neurodegeneration, August 24, 2022, Read More
Gandy, S., Simon, A. J., Steele, J. W., Lublin, A. L., Lah, J. J., Walker, L. C., Levey, A. I., Krafft, G. A., Levy, E., Checler, F., Glabe, C., Bilker, W. B., Abel, T., Schmeidler, J., & Ehrlich, M. E. Days to criterion as an indicator of toxicity associated with Human Alzheimer Amyloid-beta Oligomers, Annals of Neurology, August 1, 2010, Read More
Knight, E. M., Ruiz, H. H., Kim, S. H., Harte, J. C., Hsieh, W., Glabe, C., Klein, W. L., Attie, A. D., Buettner, C., Ehrlich, M. E., & Gandy, S. Unexpected partial correction of metabolic and behavioral phenotypes of Alzheimer’s APP/PSEN1 mice by gene targeting of diabetes/Alzheimer’s-related Sorcs1, Acta Neuropathologica Communications, February 25, 2016, Read More
Wang, E., Pan, A. L., Bagchi, P., Rangaraju, S., Seyfried, N. T., Ehrlich, M. E., Salton, S. R., & Zhang, B. Proteomic signaling of dual specificity phosphatase 4 (DUSP4) in Alzheimer’s disease, Biomolecules, January 3, 2024, Read More
Castranio, E. L., Hasel, P., Haure-Mirande, J. V., Ramirez Jimenez, A. V., Hamilton, B. W., Kim, R. D., Glabe, C. G., Wang, M., Zhang, B., Gandy, S., Liddelow, S. A., & Ehrlich, M. E. Microglial INPP5D limits plaque formation and glial reactivity in the PSAPP mouse model of Alzheimer’s disease, Alzheimer's & Dementia, November 30, 2022, Read More
Ortiz-Virumbrales, M., Moreno, C. L., Kruglikov, I., Marazuela, P., Sproul, A., Jacob, S., Zimmer, M., Paull, D., Zhang, B., Schadt, E. E., Ehrlich, M. E., Tanzi, R. E., Arancio, O., Noggle, S., & Gandy, S. CRISPR/Cas9- Correctable mutation-related molecular and physiological phenotypes in iPSC-derived Alzheimer’s PSEN (N141l) neurons, Acta Neuropathologica Communications, October 27, 2017, Read More